Aulas (PDF)

Conferência Brasileira de Câncer de Mama - LACOG GBECAM
Sexta-feira (15/03)

DANIELE ASSAD SUZUKI - GS01-02 Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2− breast cancer: KEYNOTE-756

RACHEL COSSETTI - GS01-03 Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial.

LUCIANA CASTRO GARCIA LANDEIRO - GS03-03 Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2− early breast cancer: final invasive disease–free survival (iDFS) analysis from the NATALEE trial

MAX SENNA MANO - GS03-12 Phase III study of adjuvant ado-trastuzumab emtansine vs trastuzumab for residual invasive HER2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy: KATHERINE final IDFS and updated OS analysis

CRISTIANE AMARAL DOS REIS - GS01-12 MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2- advanced breast cancer

SOLANGE MORAES SANCHES - GS01-05 Pembrolizumab + Olaparib vs Pembrolizumab + Chemotherapy After Induction With Pembrolizumab + Chemotherapy for Locally Recurrent Inoperable or Metastatic TNBC: Randomized Open-Label Phase 2 KEYLYNK-009 Study

CRISTIANO AUGUSTO ANDRADE DE RESENDE - GS01-10 HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer

TOMAS REINERT - GS03-13 Phase III study of inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutant, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: INAVO120 primary analysis

GIAMPAOLO BIANCHINI - Keynote Lecture 1 - TROP-2 ADC: targeting metastatic breast cancer

LUCIANO FERNANDES CHALA - Rastreamento de câncer de mama para população com menos de 50 anos: recomendações SBM, CBR, FEBRASGO

MARIA ISABEL ACHATZ - Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline 2024: sumário e principais mudanças

RODRIGO GUINDALINI - Análise crítica do guideline de testagem genética ASCO-SSO 2024

DEBORA GAGLIATO, CRISTIANO AUGUSTO ANDRADE DE RESENDE, TOMAS REINERT - Simpósio Satélite - Tratamento do Câncer de Mama RH+/HER2- com inibidores de ciclina: discutindo casos clínicos com especialistas

DANIELA ROSA - Avaliação de risco e tratamento de paciente na pré-menopausa com tumores luminais e envolvimento nodal

GIULIANO BEDOSCHI - Análise crítica do Especialista: Best of SABCS 2023: GS02-11 Fertility preservation and assisted reproductive technologies (ART) in breast cancer (BC) patients (pts) interrupting endocrine therapy (ET) to attempt pregnancy

ABNA FAUSTINA SOUSA VIEIRA - Disparidade e inequidades em câncer de mama: o que aprendemos em 2023

JORGE HENRIQUE SANTOS LEAL - ABSTRACT - Real-World Data on First-line Treatment of Hormone Receptor-positive, HER2-negative, Metastatic Breast Cancer in Brazil (BRAVE study - LACOG 0221)

ABSTRACT - Moderately hypofractionated post-operative radiation therapy for breast cancer: Preferences amongst radiation oncologists from countries in Latin America and the Caribbean

MANUSCRIPT - Time interval between diagnosis to treatment of breast cancer and the impact of health insurance coverage: a sub analysis of the AMAZONA III Study (GBECAM 0115)

RENATA BONADIO - MANUSCRIPT - Real-world data on triple-negative breast cancer in Latin America and the Caribbean

MANUSCRIPT - Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study

ABSTRACT - The Utility of Oncotype DX in Grade 1 Hormone Receptor-Positive Early Breast Cancer: Insights from a Multicentric Real-World Data Study

ABSTRACT - Real-world eligibility for adjuvant CDK4/6 inhibitors among patients without genomic risk for chemotherapy: a GBECAM multicenter retrospective study

ABSTRACT - Dose-dense versus 3-weekly AC during Neoadjuvant Chemoimmunotherapy for Early-Stage Triple-Negative Breast Cancer: a Real-World Safety and Effectiveness Analysis

HELOISA RESENDE - ABSTRACT - The Impact of Socioeconomic Factors on Breast Cancer Diagnosis in Latin America: The LATINA study (LACOG 0615 / MO39485)

ABSTRACT - Clinicopathological Characteristics and Factors Associated with Screening and Late-Stage Diagnosis in Patients With Breast Cancer in Latin America: The Latina Study (LACOG 0615 / MO39485)

ABSTRACT - A national survey of current scenario and future perspectives of cancer research in Brazil

MANUSCRIPT - Current scenario and future perspectives of clinical research in Brazil: a national survey

RODRIGO DIENSTMANN - Keynote Lecture 2: Mudança da prática clínica baseado em dados do mundo real: onde estamos?

ANDREA BARRIO - Simpósio Satélite - Mind the gap of luminal recurrence

ROMUALDO BARROSO DE SOUSA - Câncer de mama triplo negativo pequenos: marcadores e decisão terapêutica

HEATHER MCARTHUR - Imunoterapia neoadjuvante em tumores luminais: onde estamos

RICARDO CAPONERO - Novas evidências em surveillance: dieta, controle de peso e exercício

HEATHER MCARTHUR - Simpósio Satélite - Breaking boundaries in Triple Negative Breast Cancer